| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The molecular targets are VEGFR2, Tie2, c-Kit, and B-RAF, with Regorafenib N-oxide inhibiting these kinases in vitro; it retains the multikinase inhibitory profile of the parent drug and contributes to the antiangiogenic and antitumor effects of regorafenib, with IC50 values in the low nanomolar to micromolar range depending on the kinase.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may affect a drug's pharmacokinetics and metabolic properties, it is a cause for concern [90].
In vitro, regorafenib N-oxide-13C,d3 inhibits VEGFR2, Tie2, c-Kit, and B-RAF kinase activity in recombinant enzyme assays, and it suppresses proliferation and tube formation in endothelial cells and tumor cell lines; the deuterated form retains multikinase inhibitory activity while enabling LC-MS/MS quantification in plasma and tissue. |
| ln Vivo |
In vivo, regorafenib N-oxide inhibits tumor growth in HT-29 colorectal and MDA-MB-231 breast cancer xenograft models at a dose of 1 mg/kg, and it contributes to the antiangiogenic and antitumor effects of regorafenib; the labeled form is used to quantify plasma and tumor concentrations and to relate kinase occupancy to efficacy.
|
| Enzyme Assay |
Noncellular kinase assays incubate recombinant VEGFR2, Tie2, c-Kit, or B-RAF with a peptide substrate and [γ-32P]ATP or a fluorescent ATP analog and increasing concentrations of regorafenib N-oxide-13C,d3; phosphorylation is quantified by scintillation counting or fluorescence polarization, and IC50 values are derived, with selectivity screened against a panel of kinases.
|
| Cell Assay |
Cellular assays use endothelial cells or tumor cell lines treated with regorafenib N-oxide-13C,d3; VEGFR2 and downstream ERK/Akt phosphorylation are measured by immunoblotting, cell proliferation by BrdU incorporation, and tube formation in Matrigel, with cell viability assessed in parallel.
|
| Animal Protocol |
Animal protocols administer regorafenib N-oxide-13C,d3 orally to mice bearing HT-29 or MDA-MB-231 xenografts at doses of 1–30 mg/kg; tumor volume and body weight are monitored, and plasma and tumor concentrations are quantified by LC-MS/MS to relate multikinase occupancy to antitumor efficacy.
|
| References |
| Molecular Formula |
C2013CH12D3CLF4N4O4
|
|---|---|
| Molecular Weight |
502.83
|
| CAS # |
2140317-01-5
|
| Related CAS # |
Regorafénib N-oxyde (M2);835621-11-9
|
| Appearance |
Typically exists as solid at room temperature
|
| SMILES |
O=C(C1=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C(F)=C2)=CC=[N+]1[O-])N[13C]([2H])([2H])[2H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9887 mL | 9.9437 mL | 19.8874 mL | |
| 5 mM | 0.3977 mL | 1.9887 mL | 3.9775 mL | |
| 10 mM | 0.1989 mL | 0.9944 mL | 1.9887 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.